Navigation Links
Cellular discovery may lead to targeted treatment for rare form of anemia

CINCINNATIUniversity of Cincinnati (UC) researchers have identified the specific biological mechanisms believed to lead to a rare and incurable blood disease known as Diamond Blackfan anemia (DBA). Scientists say with further investigation, their discoveries could result in drastic changes to current thinking about treatment for this disease and may lead to promising new drug therapies.

George Thomas, PhD, Stefano Fumagalli, PhD, and collaborators report their findings online ahead of print in the journal Nature Cell Biology on Sunday, March 15, 2009. The research will also appear in the April print issue of the journal and is being presented at the 10th annual International Diamond Blackfan Anemia Consensus Conference in New York, which concludes Monday, March 16.

DBA is a rare blood disorder characterized by the bone marrow's failure to produce red blood cells. This failure is due to an intrinsic defect that makes the red blood cells prone to cell death before they mature. Red blood cells travel through the bloodstream to deliver oxygen to the body's tissues, which is critical to the health and proper function of all tissues.

According to the Centers for Disease Control and Prevention, approximately 25-35 new cases of DBA are diagnosed each year, with the majority of patients being identified before age 1. The most common treatments include blood transfusions and corticosteroids. The disease is characterized by extreme anemiawith a propensity to develop into leukemiaand often has no cure.

Using a preclinical laboratory model, Thomas' team was able to explain how cell death occurs in DBA and identified a specific step in the biological chain of events leading to disease onset where targeted medical intervention may effectively slowor even stopred blood cell death.

DBA has recently been attributed to a ribosomal protein defect that the UC team hypothesizes leads to abnormal activation of p53, causing premature death of red blood cells. P53 is a protein that normally functions to trigger "cell suicide" in response to severe cellular damage, therefore protecting the body from overgrowth of defective cells.

Previous research has attributed p53 activation to the passive diffusion of ribosomal protein L11 from the nucleolus, the part of the nucleus where ribosomes are produced to the nucleoplasm.

The UC research, however, suggests that p53 activation is not due to nucleolar breakdown, but is actually the result of an active increase in the production of L11. They suggest that in DBA, a series of L11 interactions results in cell cycle arrest and ultimately leads to cell death and anemia.

"Previous studies suggested L11 was passively coming out of the nucleolus when ribosome production was disrupted. Our study actually showed that the nucleolus stayed intact as ribosomes were still being produced, suggesting selective upregulation of L11," explains Thomas, the John and Gladys Strauss endowed professor of cancer biology at UC and scientific director at UC's Genome Research Institute. "If we can target the L11 interaction, we might be able to spare other stress pathways that mediate potential benefits of p53 induction."

Thomas believes DBA slowly evolves into cancer when this specific molecular checkpoint is lost. This results in the body being genetically reprogrammed over time, leading to the onset of additional medical problems, particularly leukemia, in DBA patients later in life.

"By understanding the chain of biological events leading to this abnormal cell death and targeting the specific molecular checkpoint that controls cell death, we may be able to develop new drugs that would interrupt or stop the process and allow the body to recover, rebuilding healthy bone marrow," adds Thomas.

This research was funded in part by the National Cancer Institute's Mouse Models in Human Cancer Consortium. In addition to Thomas and Funagalli, manuscript co-authors include Sandy Schwemberger, PhD, and George Babcock, MD, and Arti Neb-Gulati of UC; Alessandro Di Cara, PhD of Friedrich Miescher Institute for Biomedical Research in Switzerland; Francois Natt and Jonathan Hall of Novartis Institutes for Biomedical Research in Switzerland; Rosa Bernardi MD, PhD, of San Raffaele, Institute Via Olgettina in Italy; and Pier Paolo Pandolfi, MD, PhD, of Beth Israel Deaconess Medical Center in Boston.

"It is our hope that these discoveries will lead to new treatments for the disease. As anyone can imagine, in any disease where more than 90 percent of patients present before 1 year of age the families clamor for additional breakthroughs," adds Marie Arturi, executive director of the Daniella Maria Arturi Foundation. "We are deeply indebted to all who help in this effort."


Contact: Amanda J. Harper
University of Cincinnati

Related biology news :

1. A budding role for a cellular dynamo
2. Tuning in on cellular communication in the fruit fly
3. Researchers identify new function of protein in cellular respiration
4. Dictyostelium cells shown to lay breadcrumb trail as first step in multicellular formation
5. Johns Hopkins researchers detect sweet cacophony while listening to cellular cross-talk
6. Columbia to award 2008 Horwitz Prize to Arthur Horwich & Ulrich Hartl for cellular protein folding
7. UC San Diego bioengineers fill holes in science of cellular self-organization
8. A new cellular pathway linked to cancer is identified by NYU researchers
9. Cellular self-eating promotes pancreatitis
10. LIAI researchers discover new cellular mechanism that will significantly advance vaccine development
11. Researchers discover critical detail of cellular defense against genetic mistakes
Post Your Comments:
(Date:11/17/2015)... Mass. , Nov. 17, 2015 Pressure ... leader in the development and sale of broadly enabling, ... worldwide life sciences industry, today announced it has received ... its $5 million Private Placement (the "Offering"), increasing the ... $4,025,000.  One or more additional closings are expected in ...
(Date:11/12/2015)... , Nov. 12, 2015  A golden retriever ... Duchenne muscular dystrophy (DMD) has provided a new lead ... Children,s Hospital, the Broad Institute of MIT and Harvard ... Brazil . Cell, pinpoints ... dogs "escape" the disease,s effects. The Boston Children,s lab ...
(Date:11/12/2015)... , Nov. 11, 2015   Growing ... reliable analytical tools has been paving the way ... qualitative determination of discrete analytes in clinical, agricultural, ... are being predominantly used in medical applications, however, ... environmental sectors due to continuous emphasis on improving ...
Breaking Biology News(10 mins):
(Date:12/1/2015)... 2015 ) ... U.K. Virology and Bacteriology Testing Market: Sales ... Supplier Shares by Test, Innovative Technologies, Competitive ... --> ) has announced ... and Bacteriology Testing Market: Sales and Volume ...
(Date:11/30/2015)... , Dec. 1, 2015  An interventional radiology technique ... to the preliminary results of a study being presented today ... North America (RSNA). ... done for decades by interventional radiologists as a way to ... the procedure as a means of treating obesity is new. ...
(Date:11/30/2015)... /PRNewswire/ - Zenith Epigenetics Corp. ("Zenith" or the "Company") today ... to its Board of Directors to replace Dr. ... wealth of experience as co-founder of Resverlogix, with expertise in ... --> --> Dr. Wong remarked, "I am ... Zenith,s long standing expertise in epigenetics and the advanced stage ...
(Date:11/30/2015)... JACKSONVILLE, Florida , November 30, 2015 ... company specializing in the development of innovative peptide and ... & metastatic disease, today announced it will be presenting ... Event on December 1, 2015 at 2.30 PM PT. ... member and Strategic Advisor will be giving the presentation ...
Breaking Biology Technology: